Articles

Welcome to Volume 13, Issue #6 (June 2014) of Pharma Marketing News.

PMN1306-01Issue: Vol. 13, No. 6: June 2014Find other articles in related Topic Areas: eMarketing and ePromotionDirect-to-Consumer (DTC) Advertising & MarketingRegulatory Compliance

This article reviews the FDA's guidance on how pharma marketers must present both benefit and risk information within a

This article reviews the FDA's guidance on how pharmaceutical companies can respond to misinformation related to a firm's own FDA-approved or -cleared products when that information is created or disseminated by independent third parties on the Internet or through social media, regardless of whether that misinformation appears on a firm's own forum or an independent third-party forum or website.

This article reviews BI's 'playbook' -- titled 'How pharma TweetChats can drive healthcare innovation' -- which provides detailed insights for planning and delivering successful pharma TweetChats. The authors of the playbook -- Patricia Alves, Social Media Community Manager, and Jaclyn Fonteyne, Social Media Specialist, at BI -- were also interviewed for this article.

Welcome to Volume 13, Issue #5 (May 2014) of Pharma Marketing News.

According to the latest Cegedim Strategic Data (CSD) Audit, the 20 pharma companies that spent the most on total promotion -- which includes traditional professional detailing, eDetailing, Direct-to-Consumer (DTC) advertising, professional meetings, and journal advertising -- spent a total of $14,784 Bn in 2013. This article analyzes data from several sources to determine how much of this is allocated to various media and channels and also looks at the trends for several channels.

'The medical conference is dead, long live the medical conference,' is the title of a SlideShare presentation by Len Starnes (@lenstarnes), a respected digital health-care consultant. Starnes is referring to the emergence of the 'virtual' medical conference, which he believes will soon be adopted in one form or another by all medical societies. This article describes the changes occurring viz-a-viz major medical conferences and the impact this will have on the pharmaceutical industry, medical societies, healthcare professionals, and patients.

Welcome to Volume 13, Issue #4 (April 2014) of Pharma Marketing News.

The comments are in! As usual, the pharma industry waited until the last minute to submit comments to FDA Docket 2013-N-1430 regarding recent FDA social media draft guidance. This article provides highlights from submissions by Novartis, Shire, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), Klick Health, the Social Media Compliance Council (SMCC), the Coalition for Healthcare Communication (CHC), and the Digital Health Coalition (DHC), and other interested parties.